A Phase IIb/III, Double-Blind, Placebo-Controlled, Randomized Study Investigating the Safety, Tolerability and Efficacy of Flupirtine as Adjunct to Opioids When Administered to Cancer Subjects Who Are Experiencing Pain With Neuropathic Features
Phase of Trial: Phase II/III
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Flupirtine (Primary)
- Indications Cancer pain; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Relevare Pharmaceuticals
- 05 Jul 2018 Status changed from recruiting to completed.
- 06 May 2012 New source identified and integrated (European Clinical Trials Database).
- 06 May 2012 Status changed from planning to recruiting, according to the European Clinical Trials Database.